Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.793,11
0,10%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Evelo Biosciences Inc (EVLO) Evelo Biosciences Inc (EVLO) Notizie

EVLO

Evelo Biosciences (EVLO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EVLO
DataOraFonteTitoloSimboloCompagnia
26/01/202423:30Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EVLOEvelo Biosciences Inc
26/01/202423:29Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
26/01/202423:27Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EVLOEvelo Biosciences Inc
26/01/202423:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
12/12/202313:43Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EVLOEvelo Biosciences Inc
12/12/202313:42Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
01/12/202313:11Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
09/11/202323:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
09/11/202302:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
17/10/202313:00GlobeNewswire Inc.Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisNASDAQ:EVLOEvelo Biosciences Inc
21/08/202323:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
18/08/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVLOEvelo Biosciences Inc
14/08/202313:30GlobeNewswire Inc.Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
10/08/202322:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:EVLOEvelo Biosciences Inc
18/07/202313:27IH Market NewsTuesday’s Wall Street Highlights: Novartis, BofA, Dollar General, Uber, Masimo and moreNASDAQ:EVLOEvelo Biosciences Inc
12/07/202322:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
12/07/202313:30GlobeNewswire Inc.Evelo Biosciences Closes $25.5 Million Private PlacementNASDAQ:EVLOEvelo Biosciences Inc
10/07/202313:30GlobeNewswire Inc.Evelo Biosciences Announces $25.5 Million Private PlacementNASDAQ:EVLOEvelo Biosciences Inc
29/06/202315:00GlobeNewswire Inc.Evelo Biosciences Announces Reverse Stock Split EffectiveNASDAQ:EVLOEvelo Biosciences Inc
23/06/202322:55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EVLOEvelo Biosciences Inc
12/06/202322:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:EVLOEvelo Biosciences Inc
12/06/202314:22Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:EVLOEvelo Biosciences Inc
16/05/202312:00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:EVLOEvelo Biosciences Inc
10/05/202323:12Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:EVLOEvelo Biosciences Inc
28/04/202322:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:EVLOEvelo Biosciences Inc
28/04/202322:20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:EVLOEvelo Biosciences Inc
18/04/202323:24Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:EVLOEvelo Biosciences Inc
18/04/202323:10Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:EVLOEvelo Biosciences Inc
16/03/202313:30Edgar (US Regulatory)Annual Report (10-k)NASDAQ:EVLOEvelo Biosciences Inc
16/03/202312:00GlobeNewswire Inc.Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EVLO

La tua Cronologia

BIT
F22627
Vontobel Financial Produ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network